Global Antibody Drug Conjugates (ADCs) Market Size & Trends Report Segmented by Product (Kadcyla, Padcev, Enhertu, Adcetris, Trodelvy), Application (Breast Cancer, Blood Cancer), Target (HER2, CD22, CD30), Technology & Regional Forecasts to 2030

The antibody drug conjugates (ADCs) market is projected to grow at a CAGR of ~9% over the forecast period. Major factors driving growth include the growing prevalence of cancer, increasing demand for targeted cancer therapies, advancement in ADC technology, growing investment in R&D for introducing new antibody-drug conjugates, and increasing approvals by regulatory bodies such as the FDA and EMA for ADCs. However, the market encounters certain challenges, including the high cost of development, stringent regulatory requirements that make the approval process lengthy and expensive, and increasing competition from emerging therapies. 

Report Overview

Antibody-drug conjugates or ADCs are a novel class of highly potent biopharmaceuticals consisting of a monoclonal antibody chemically linked to a biologically active drug or cytotoxic compound. These targeted therapies harness the precise targeting capabilities of antibodies, enabling accurate differentiation between healthy and cancerous tissues, while delivering the cell-killing effects of cytotoxic agents. An ideal ADC has:

• A highly selective monoclonal antibody (mAb) for a tumor-associated antigen that has restricted or no expression on normal (healthy) cells
• A potent cytotoxic agent (generally a small molecule drug with high systemic toxicity) designed to induce target cell death after being internalized in the tumor cell and released
• A linker that is stable in circulation, but releases the cytotoxic agent in target cells

To learn more about this report, download the PDF brochure

Growing prevalence of cancer is expected to drive market growth

Cancer remains one of the leading causes of death globally. According to GLOBOCAN 2024, in 2022, nearly 20 million new cancer cases were reported, alongside 9.7 million cancer-related deaths worldwide. Therapeutic approaches for treating cancer or tumors include chemotherapy, immunotherapy, radiation therapy, stem cell therapy, laser treatment, hyperthermia, surgery, and photodynamic therapy, among others. Among these, chemotherapy remains the primary treatment method.

However, antibody-drug conjugates (ADCs) are rapidly gaining attention due to their unique capability to combine targeted therapy with potent cytotoxic agents while leaving healthy cells unharmed. This innovative approach provides a promising solution for treating various types of cancers, including those resistant to conventional therapies. To date, 14 ADCs have received market approval for the treatment of different cancers, with over 200 currently undergoing clinical development. Further, ADCs are revolutionizing cancer treatment by offering a highly specific mechanism of action, delivering targeted and effective therapy, and bringing new hope to cancer patients worldwide.

Technological advancements in antibody-drug conjugate (ADC) technology to propel market growth

Continuous advancements in the design and development of antibody-drug conjugates (ADCs) have significantly improved their efficacy and safety, making them increasingly attractive as treatment options. These innovations span several critical areas, including antibody engineering, linker technology, cytotoxic payloads, and manufacturing processes.

One breakthrough is the adoption of site-specific conjugation techniques, which provide precise control over the drug-to-antibody ratio, enhancing the consistency and therapeutic performance of ADCs. Another key innovation is the development of novel linkers that respond to specific conditions, such as the low pH in the tumor microenvironment, enabling targeted drug release and reducing off-target toxicity. Additionally, advances in antibody engineering and selection have led to the creation of antibodies with enhanced binding specificity, affinity, and pharmacokinetics, further boosting the potency and effectiveness of ADCs. Improvements in manufacturing technologies, such as the integration of single-use systems, have addressed some of the production challenges, increasing efficiency and scalability. As research in ADCs continues to progress, even more sophisticated and effective technologies are expected to emerge, broadening the scope of their applications.

To learn more about this report, download the PDF brochure

Competitive Landscape Analysis

The global antibody drug conjugates (ADCs) market is marked by the presence of established and emerging market players such as Takeda Pharmaceutical Company Ltd.; AstraZeneca PLC; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AbbVie-s; Gilead Sciences, Inc.; Merck & Co.; ADC Therapeutics SA; Bolt Biotherapeutics; "https://www.mersana.com/">Mersana Therapeutics; and Daiichi Sankyo Company Ltd.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and investments.

Report Scope

Report Metric	Details
Base Year Considered	2024
Historical Data	2023 - 2024
Forecast Period	2025 - 2030
Growth Rate	9%
Market Drivers	Growing prevalence of cancer Advancement in ADC technology Increasing demand for targeted cancer therapies Growing investment in R&D for introducing new antibody drug conjugates Increasing approvals by regulatory bodies such as the FDA and EMA for ADCs
Attractive Opportunities	Expansion into non-oncology indications Leveraging ADCs in combination with existing immunotherapies Rising demand for targeted therapies
Segment Scope	Product, Application, Target, and Technology
Regional Scope	North America (US & Canada) Europe (UK, Germany, France, Italy, Spain, Rest of Europe) Asia Pacific (China, India, Japan, Rest of Asia Pacific) Latin America Middle East & Africa
Key Companies Mapped	Takeda Pharmaceutical Company Ltd.; AstraZeneca PLC; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AbbVie-s; Gilead Sciences, Inc.; Merck & Co.; ADC Therapeutics SA; Bolt Biotherapeutics; Mersana Therapeutics; and Daiichi Sankyo Company Ltd.
Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis

Global Antibody Drug Conjugates (ADCs) Market Segmentation

This report by Medi-Tech Insights provides thesize of the global antibody drug conjugates (ADCs) market at theregional- and country-level from 2023 to 2030. The report further segments the market based on product, application, target, and technology.

Market Size & Forecast (2023-2030), By Product, USD Million

• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

Market Size & Forecast (2023-2030), By Application, USD Million

• Breast Cancer
• Blood Cancer
• Other Cancers

Market Size & Forecast (2023-2030), By Target, USD Million

• HER2
• CD22
• CD30
• Others

Market Size & Forecast (2023-2logy USD Million

• Linker Type
• Cleavable Linker
• Non-cleavable Linker
• Linker less
• Payload Technology
• MMAE/ Auristatin
• Maytansinoids
• Camptothecin
• Others

Market Size & Forecast (2023-2030), By Region, USD Million

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa